Business Context and Reporting Period
This Form 8-K Current Report was filed by Alector, Inc. on February 7, 2022. The filing discloses a significant change in executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) and the transition of the interim CFO.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Appointment of CFO: Marc Grasso, M.D., was appointed as Chief Financial Officer, effective February 7, 2022.
- Departure of Interim CFO: Linda Rubinstein ceased serving as interim CFO on February 7, 2022.
- Role Transition: Ms. Rubinstein continued as Principal Financial Officer and Principal Accounting Officer until February 25, 2022, at which point Dr. Grasso assumed these roles.
Management Commentary and Compensation Details
Dr. Grasso joins Alector from Kura Oncology, Inc., where he served as CFO and Chief Business Officer. His compensation package, detailed in an offer letter dated February 4, 2022, includes:
- Base Salary: $480,000 annually.
- Performance Bonus: Eligible for up to 40% of base salary.
- Sign-on Bonus: $103,000.
- Equity: Stock option to purchase 450,000 shares of common stock, vesting over four years.
- Severance: Entitled to Tier 2 level severance under the company's standard change in control and severance agreement.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 450,000 stock options granted to Dr. Grasso in Exhibit 10.1.
- Review the specific terms of the Tier 2 severance agreement referenced in the filing.
- Confirm the exact date of the transition of Principal Financial Officer duties from Ms. Rubinstein to Dr. Grasso (February 25, 2022).
- Check for any subsequent filings regarding the impact of this leadership change on the company's financial reporting or strategic direction.